Alpine Immune Sciences price target raised to $22 from $14 at Oppenheimer

Oppenheimer raised the firm’s price target on Alpine Immune Sciences to $22 from $14 and keeps an Outperform rating on the shares. The firm is highlighting Alpine’s ongoing autoimmune nephropathy programs with povetacicept via a deep dive on IgA nephropathy, which Oppenheimer has formally incorporated into its model and valuation. The firm has been historically vocal for the Hit-1-targeting approaches in IgAN and highlights povetacicept’s potential as a convenient once-monthly agent to address the disease.